Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding

Background: Nivolumab is a programmed cell death-1 receptor (PD-1) inhibitor approved by the U.S. Food and Drug Administration for the treatment of melanoma, non-small cell lung cancer, renal cancer, and classical Hodgkin lymphoma. For patients on immune checkpoint modulators such as PD-1 inhibitors, cutaneous immune-related adverse events (irAEs) are a significant concern. Dermatologic toxicities include pruritus, vitiligo, eczema, lichenoid eruptions and Stevens-Johnson syndrome. Vitiligo-like depigmentation has been well described in melanoma patients receiving treatment with PD-1 inhibitors.

http://ift.tt/2sXQC3R